Table 2 Number of studies per country and vaccine type
Country | Number of studies (%)a | Type of vaccine | Number of studies (%)a |
|---|---|---|---|
Australia | 3 (7.1) | Childhood (combination) vaccines | 6 (14.3) |
Belgium | 1 (2.4) | General vaccines | 3 (7.1) |
Canada | 1 (2.4) | Hepatitis B (HepB) vaccine | 2 (4.8) |
China | 3 (7.1) | Herpes zoster vaccine | 1 (2.4) |
Europe (not specified) | 1 (2.4) | Human Papilloma Virus (HPV) vaccine | 9 (21.4) |
France | 2 (4.8) | Hypothetical vaccine | 5 (11.9) |
Germany | 3 (7.1) | Influenza vaccine | 8 (19.0) |
Hong Kong | 3 (7.1) | Leptospirosis vaccine | 1 (2.4) |
Hungary | 1 (2.4) | Meningococcal (B) vaccine | 3 (7.1) |
Italy | 1 (2.4) | Pertussis vaccine | 1 (2.4) |
Japan | 2 (4.8) | Pneumococcal vaccine | 1 (2.4) |
Netherlands, the | 9 (21.4) | Rotavirus vaccine | 2 (4.8) |
Philippines, the | 1 (2.4) | Tetanus-Diphtheria-Pertussis (Tdap) vaccine | 1 (2.4) |
Poland | 2 (4.8) | Travel vaccines | 1 (2.4) |
South-Africa | 1 (2.4) | Varicella vaccine | 1 (2.4) |
Spain | 2 (4.8) | Â | Â |
Sweden | 1 (2.4) | Â | Â |
Thailand | 1 (2.4) | Â | Â |
United Kingdom | 2 (4.8) | Â | Â |
Unites States of America | 7 (16.7) | Â | Â |
Vietnam | 1 (2.4) | Â | Â |